Purpose: Camelid single-domain antibody-fragments (sdAb) have beneficial pharmacokinetic properties, and those targeted to HER2 can be used for imaging of HER2-overexpressing cancer. Labeled with a therapeutic radionuclide, they may be used for HER2-targeted therapy. Here, we describe the generation of a 131I-labeled sdAb as a theranostic drug to treat HER2-overexpressing cancer.Experimental De...

The Treatment Paradigm (Figure 1) Methimazole (MMI) was started 3 to 6 months before 131I therapy to restore euthyroidism and was discontinued 5 days (T-5) before 131I was initiated. On the same day, lithium, 900 mg/day was started. Seven days after 131I was administered (day T0), lithium was withdrawn, comprising 12 days of lithium, and oral prednisone was started at 0.5 mg/kg daily to avoid 1...

To the Editor: Earlier studies demonstrated unexpected decrease of radioiodine (131I) renal excretion in patients adherent to low-iodine diet before 131I treatment while receiving furosemide [1,2]. This effects seems specific for humans, since it was not confirmed in a study on mice treated with low-iodine diet [3]. Other researchers [4-7] observed increase of 131I uptake to thyroid tissue or t...

We previously have reported that radioiodinated anti-tenascin monoclonal antibody 81C6 exhibits therapeutic potential against both s.c. and intracranial human glioma xenografts in athymic mice and rats. Herein we report the selective tumor localization of 131I-labeled 81C6 in patients with gliomas and other intracranial malignancies. Nine patients were simultaneously administered 5-50 mg of 131...

A 71-year-old male patient was diagnosed with papillary carcinoma follicular variant after bilateral total thyroidectomy and radioactive iodine treatment applied. The post-therapeutic whole-body scan demonstrated a focal 131I uptake in the right lobe of liver upper quadrant abdomen. Single-photon emission computed tomography/computed tomography (SPECT/CT) performed to determine precise localiza...

An anti-carcinoembryonic antigen murine monoclonal antibody designated NP-4, and its F(ab')2 and Fab' fragments, were coupled to the 1/1 mixture of 1-isothiocyanato-benzyl-3-methyl- and 1-methyl-3-isothiocyanato-benzyl-diethylenetriaminepentaacetic acid chelate and labeled with 111In or 88Y. Biodistribution studies in nude mice bearing a human colonic tumor xenograft were performed with these l...

OBJECTIVE This trial was conducted to evaluate the ability of pazopanib to overcome therapeutic 131I resistance. MATERIALS, METHODS AND PATIENTS This phase 1 trial assesses the combination of pazopanib and escalating doses of radioiodine (131I) in patients with recurrent or metastatic thyroid cancer that are borderline or relatively iodine refractory. Radioiodine uptake scans were assessed po...

Five patients treated with intraperitoneal 131I-labeled mouse monoclonal antibody for ovarian cancer also received i.v. exogenous polyclonal human anti-murine immunoglobulin antibody. The pharmacokinetics of 131I-labeled monoclonal antibody in these patients were compared with those of 28 other patients receiving i.p.-radiolabeled monoclonal antibody for the first time without exogenous human a...

Defective apoptotic program due to the overexpression of the anti-apoptotic Bcl-2 protein of the outer mitochondrial membrane may be a cause of the poor response of malignant pheochromocytoma to 131I-MIBG therapy. We report a case of malignant pheochromocytoma which showed early intense uptake and immediate rapid washout of 99mTc-tetrofosmin characterizing the overexpression of anti-apoptotic B...